Stroke prevention in atrial fibrillation: Can we do better?

Deirdre Lane; Gregory Lip

doi:10.1038/nrcardio.2016.117

Stroke prevention in atrial fibrillation: Can we do better?

Deirdre Lane, Gregory Lip

Cardiovascular Sciences

Research output: Contribution to journal › Book/Film/Article review › peer-review

1 Citation (Scopus)

169 Downloads (Pure)

Abstract

Clinical guidelines advocate oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation and ≥1 risk factors for stroke, but 40% of eligible patients receive aspirin, and those at greatest risk are least likely to be prescribed OAC. Why is there a discrepancy between guidelines and clinical practice?

Original language	English
Journal	Nature Reviews Cardiology
Early online date	28 Jul 2016
DOIs	https://doi.org/10.1038/nrcardio.2016.117
Publication status	E-pub ahead of print - 28 Jul 2016

Access to Document

10.1038/nrcardio.2016.117

Lane_&_Lip_Stroke_prevention_in_Nature_Reviews_Cardiology_2016
Published version of record available online at: http://dx.doi.org/10.1038/nrcardio.2016.117 Checked for eligibility: 13/07/2016
Accepted author manuscript, 101 KBLicence: None: All rights reserved

Cite this

@article{2f9b8427414e4c95b98bd82e5cb3bde3,

title = "Stroke prevention in atrial fibrillation: Can we do better?",

abstract = "Clinical guidelines advocate oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation and ≥1 risk factors for stroke, but 40% of eligible patients receive aspirin, and those at greatest risk are least likely to be prescribed OAC. Why is there a discrepancy between guidelines and clinical practice?",

author = "Deirdre Lane and Gregory Lip",

year = "2016",

month = jul,

day = "28",

doi = "10.1038/nrcardio.2016.117",

language = "English",

journal = "Nature Reviews Cardiology",